The Community Guide

- gsearch

Search Results

Narrow Results:

2021 3
2019 2
2018 4
2017 1
2016 1
2015 5
2014 1
2013 3
2012 1
2010 1
1988 1
1983 1

North America 1
United States 2

Journal Article 24

1 - 20 of 24 Results

Refine Results

Refine Results:

Improving the performance of factor VIII inhibitor tests in hemophilia A

CITE Title : Improving the performance of factor VIII inhibitor tests in hemophilia A Personal Author(s) : Miller, Connie H. Published Date : Sep 28 2015 Source : Thromb Res. 136(6):1047-1048. URL : https://stacks.cdc.gov/view/cdc/37564 Miller, Connie H. (2015). Improving the performance of factor VIII inhibitor tests in hemophilia A. 136(6). Miller, Connie H. "Improving the performance of factor VIII inhibitor tests in hemophilia A" 136, no. 6 (2015) Miller, Connie H. "Improving the performance of factor VIII inhibitor tests in hemophilia A" vol. 136, no. 6, 2015 Export RIS Citation Information.

:

Miller, Connie H.

Sep 28 2015 | Thromb Res. 136(6):1047-1048.

No Description
Females with FVIII and FIX deficiency have reduced joint range of motion

CITE Title : Females with FVIII and FIX deficiency have reduced joint range of motion Personal Author(s) : Sidonio, Robert F.;Mili, Fatima D.;Li, Tengguo;Miller, Connie H.;Hooper, William C.;DeBaun, Michael R.;Soucie, Michael; Corporate Authors(s) : The Hemophilia Treatment Centers Network Published Date : May 21 2014 Source : Am J Hematol. 2014; 89(8):831-836. URL : https://stacks.cdc.gov/view/cdc/31743 Sidonio, Robert F. et al. (2014). Females with FVIII and FIX deficiency have reduced joint range of motion. 89(8). Sidonio, Robert F. et al. "Females with FVIII and FIX deficiency have reduced joint range of motion" 89, no. 8 (2014) Sidonio, Robert F. et al. "Females with FVIII and FIX deficiency have reduced joint range of motion" vol. 89, no. 8, 2014 Export RIS Citation Information.

:

Sidonio, Robert F. ;

Mili, Fatima D.

May 21 2014 | Am J Hematol. 2014; 89(8):831-836.

:

Little is known about rates of joint bleeding among females with FVIII/FIX deficiency or hemophilia carriers. In a cross-sectional study, we tested th...
The effects of the AIDS epidemic on the safety of the nation's blood supply.

CITE Title : The effects of the AIDS epidemic on the safety of the nation's blood supply. Personal Author(s) : Petricciani, J C;Epstein, J S; Published Date : 1988 May-Jun;May-Jun 1988; Source : Public Health Rep. 103(3):236-241 URL : https://stacks.cdc.gov/view/cdc/63161 Petricciani, J C and Epstein, J S (1988). The effects of the AIDS epidemic on the safety of the nation's blood supply.. 103(3). Petricciani, J C and Epstein, J S "The effects of the AIDS epidemic on the safety of the nation's blood supply." 103, no. 3 (1988) Petricciani, J C and Epstein, J S "The effects of the AIDS epidemic on the safety of the nation's blood supply." vol. 103, no. 3, 1988 Export RIS Citation Information.

:

Petricciani, J C ;

Epstein, J S

1988 May-Jun | Public Health Rep. 103(3):236-241

:

Present safeguards for the blood supply consist of three tiers of protection: donor deferral based on a donor's history of risk factors, confidential ...
Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients

CITE Title : Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients Personal Author(s) : Rampersad, A. G.;Boylan, B.;Miller, C. H.;Shapiro, A.; Published Date : Jul 13 2018;9-2018; Source : Haemophilia. 24(5):807-814 URL : https://stacks.cdc.gov/view/cdc/70144 Rampersad, A. G. et al. (2018). Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients. 24(5). Rampersad, A. G. et al. "Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients" 24, no. 5 (2018) Rampersad, A. G. et al. "Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients" vol. 24, no. 5, 2018 Export RIS Citation Information.

:

Rampersad, A. G. ;

Boylan, B.

Jul 13 2018 | Haemophilia. 24(5):807-814

:

Introduction:Accurate diagnosis of an inhibitor, a neutralizing antibody to infused factor VIII (FVIII), is essential for appropriate management of ha...
Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay

CITE Title : Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay Personal Author(s) : Miller, Connie H. Published Date : 9 2021;9-2021; Source : Haemophilia. 27(5):823-829 URL : https://stacks.cdc.gov/view/cdc/112553 Miller, Connie H. (2021). Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay. 27(5). Miller, Connie H. "Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay" 27, no. 5 (2021) Miller, Connie H. "Monitoring of von Willebrand Factor Inhibitors in Patients with Type 3 von Willebrand Disease Using a Quantitative Assay" vol. 27, no. 5, 2021 Export RIS Citation Information.

:

Miller, Connie H.

9 2021 | Haemophilia. 27(5):823-829

:

Background:Antibodies inhibiting von Willebrand factor (VWF) develop in a subset of patients with Type 3 von Willebrand disease (VWD3) and may be dete...
A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States

CITE Title : A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States Personal Author(s) : Soucie, J. Michael;Miller, Connie H.;Kelly, Fiona M.;Payne, Amanda B.;Creary, Melissa;Bockenstedt, Paula L.;Kempton, Christine L.;Manco-Johnson, Marilyn J.;Neff, Anne T.; Corporate Authors(s) : Haemophilia Inhibitor Research Study Investigators Published Date : Nov 22 2013 Source : Haemophilia. 20(2):230-237. URL : https://stacks.cdc.gov/view/cdc/32548 Soucie, J. Michael et al. (2013). A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States. 20(2). Soucie, J. Michael et al. "A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States" 20, no. 2 (2013) Soucie, J. Michael et al. "A Study of Prospective Surveillance for Inhibitors among Persons with Haemophilia in the United States" vol. 20, no. 2, 2013 Export RIS Citation Information.

:

Soucie, J. Michael ;

Miller, Connie H.

Nov 22 2013 | Haemophilia. 20(2):230-237.

:

IntroductionInhibitors are a rare but serious complication of treatment of patients with haemophilia. Phase III clinical trials enroll too few patient...
Genetic causes of haemophilia in women and girls

CITE Title : Genetic causes of haemophilia in women and girls Personal Author(s) : Miller, Connie H.;Bean, Christopher J.; Published Date : 3 2021;3-2021; Source : Haemophilia. 27(2):e164-e179 URL : https://stacks.cdc.gov/view/cdc/106467 Miller, Connie H. and Bean, Christopher J. (2021). Genetic causes of haemophilia in women and girls. 27(2). Miller, Connie H. and Bean, Christopher J. "Genetic causes of haemophilia in women and girls" 27, no. 2 (2021) Miller, Connie H. and Bean, Christopher J. "Genetic causes of haemophilia in women and girls" vol. 27, no. 2, 2021 Export RIS Citation Information.

:

Miller, Connie H.

;

Bean, Christopher J.

3 2021 | Haemophilia. 27(2):e164-e179

:

Women and girls reported as "haemophilic females" may have complex genetic causes for their haemophilia phenotype. In addition, women and girls may ha...
Parvovirus 4–like Virus in Blood Products

CITE Title : Parvovirus 4–like Virus in Blood Products Personal Author(s) : Szelei, Jozsef;Liu, Kaiyu;Li, Yi;Fernandes, Sandra;Tijssen, Peter; Published Date : Mar 2010 Source : Emerg Infect Dis. 16(3):561-564. URL : https://stacks.cdc.gov/view/cdc/17964 Szelei, Jozsef et al. (2010). Parvovirus 4–like Virus in Blood Products. 16(3). Szelei, Jozsef et al. "Parvovirus 4–like Virus in Blood Products" 16, no. 3 (2010) Szelei, Jozsef et al. "Parvovirus 4–like Virus in Blood Products" vol. 16, no. 3, 2010 Export RIS Citation Information.

:

Szelei, Jozsef ;

Liu, Kaiyu

Mar 2010 | Emerg Infect Dis. 16(3):561-564.

:

Porcine plasma and factor VIII preparations were screened for parvovirus 4 (PARV)-like viruses. Although the prevalence of PARV4-like viruses in plasm...
Women and Girls with Hemophilia Receiving Care at Specialized Hemophilia Treatment Centers in the United States

CITE Title : Women and Girls with Hemophilia Receiving Care at Specialized Hemophilia Treatment Centers in the United States Personal Author(s) : Miller, Connie H.;Soucie, J. Michael;Byams, Vanessa R.;Payne, Amanda B.;Sidonio, Robert F.;Buckner, Tyler W.;Bean, Christopher J.; Published Date : 11 2021 Source : Haemophilia. 27(6):1037-1044 URL : https://stacks.cdc.gov/view/cdc/112455 Miller, Connie H. et al. (2021). Women and Girls with Hemophilia Receiving Care at Specialized Hemophilia Treatment Centers in the United States. 27(6). Miller, Connie H. et al. "Women and Girls with Hemophilia Receiving Care at Specialized Hemophilia Treatment Centers in the United States" 27, no. 6 (2021) Miller, Connie H. et al. "Women and Girls with Hemophilia Receiving Care at Specialized Hemophilia Treatment Centers in the United States" vol. 27, no. 6, 2021 Export RIS Citation Information.

:

Miller, Connie H. ;

Soucie, J. Michael

11 2021 | Haemophilia. 27(6):1037-1044

:

Introduction:Females may have hemophilia with the same factor VIII (FVIII) or factor IX (FIX) levels as affected males. Characterization of females wi...
Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors

CITE Title : Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors Personal Author(s) : Sabatino, Denise E.;Pipe, Steven W.;Nugent, Diane J.;Soucie, J. Michael;Hooper, W. Craig;Hoots, W. Keith;DiMichele, Donna M.; Published Date : Jul 2019 Source : Haemophilia. 25(4):575-580 URL : https://stacks.cdc.gov/view/cdc/88161 Sabatino, Denise E. et al. (2019). Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. 25(4). Sabatino, Denise E. et al. "Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors" 25, no. 4 (2019) Sabatino, Denise E. et al. "Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors" vol. 25, no. 4, 2019 Export RIS Citation Information.

:

Sabatino, Denise E. ;

Pipe, Steven W.

Jul 2019 | Haemophilia. 25(4):575-580

:

IntroductionThe major complication of protein replacement therapy for haemophilia A is the development of anti-FVIII antibodies or inhibitors that occ...
treatment products

CITE Title : treatment products Personal Author(s) : Payne, Amanda B.;Ellingsen, Dorothy;Driggers, Jennifer;Bean, Christopher J.;Miller, Connie H.; Published Date : December 06 2019 Source : Haemophilia. 26(1):e28-e30 URL : https://stacks.cdc.gov/view/cdc/94606 Payne, Amanda B. et al. (2019). treatment products. 26(1). Payne, Amanda B. et al. "treatment products" 26, no. 1 (2019) Payne, Amanda B. et al. "treatment products" vol. 26, no. 1, 2019 Export RIS Citation Information.

:

Payne, Amanda B. ;

Ellingsen, Dorothy

December 06 2019 | Haemophilia. 26(1):e28-e30

No Description
Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance

CITE Title : Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance Personal Author(s) : Miller, C. H.;Platt, S. J.;Rice, A. S.;Kelly, F.;Soucie, J. M.; Corporate Authors(s) : Hemophilia Inhibitor Research Study Investigators Published Date : 6 2012;6-2012; Source : J Thromb Haemost. 10(6):1055-1061 URL : https://stacks.cdc.gov/view/cdc/33790 Miller, C. H. et al. (2012). Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance. 10(6). Miller, C. H. et al. "Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance" 10, no. 6 (2012) Miller, C. H. et al. "Validation of Nijmegen-Bethesda Assay Modifications to Allow Inhibitor Measurement during Replacement Therapy and Facilitate Inhibitor Surveillance" vol. 10, no. 6, 2012 Export RIS Citation Information.

:

Miller, C. H. ;

Platt, S. J.

6 2012 | J Thromb Haemost. 10(6):1055-1061

:

BackgroundAs part of a pilot U.S. inhibitor surveillance project initiated at the Centers for Disease Control and Prevention (CDC) in 2006, centralize...
Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening

CITE Title : Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening Personal Author(s) : Miller, Connie H.;Rice, Anne S.;Boylan, Brian;Payne, Amanda B.;Kelly, Fiona M.;Escobar, Miguel A.;Gill, Joan;Leissinger, Cindy;Soucie, J. Michael; Corporate Authors(s) : Hemophilia Inhibitor Research Study Investigators Published Date : 10 2015;10-2015; Source : Am J Hematol. 90(10):871-876 URL : https://stacks.cdc.gov/view/cdc/36468 Miller, Connie H. et al. (2015). Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. 90(10). Miller, Connie H. et al. "Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening" 90, no. 10 (2015) Miller, Connie H. et al. "Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening" vol. 90, no. 10, 2015 Export RIS Citation Information.

:

Miller, Connie H. ;

Rice, Anne S.

10 2015 | Am J Hematol. 90(10):871-876

:

Characteristics of inhibitors identified by prospective screening may differ from those detected clinically. In a prospective study at 17 hemophilia c...
Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study

CITE Title : Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study Personal Author(s) : Miller, Connie H.;Rice, Anne S.;Boylan, Brian;Shapiro, Amy D.;Lentz, Steven R.;Wicklund, Brian M.;Kelly, Fiona M.;Soucie, J. Michael; Corporate Authors(s) : Hemophilia Inhibitor Research Study Investigators Published Date : 7 2013;7-2013; Source : J Thromb Haemost. 11(7):1300-1309 URL : https://stacks.cdc.gov/view/cdc/31742 Miller, Connie H. et al. (2013). Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study. 11(7). Miller, Connie H. et al. "Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study" 11, no. 7 (2013) Miller, Connie H. et al. "Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study" vol. 11, no. 7, 2013 Export RIS Citation Information.

:

Miller, Connie H. ;

Rice, Anne S.

7 2013 | J Thromb Haemost. 11(7):1300-1309

:

BackgroundDetection and validation of inhibitors (antibodies) to hemophilia treatment products are important for clinical care, evaluation of product ...
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay

CITE Title : Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay Personal Author(s) : Boylan, Brian;Rice, Anne S.;Dunn, Amy L.;Tarantino, Michael D.;Brettler, Doreen B.;Barrett, John C.;Miller, Connie H.; Corporate Authors(s) : Hemophilia Inhibitor Research Study Investigators Published Date : 1 2015;1-2015; Source : J Thromb Haemost. 13(1):47-53 URL : https://stacks.cdc.gov/view/cdc/30356 Boylan, Brian et al. (2015). Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. 13(1). Boylan, Brian et al. "Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay" 13, no. 1 (2015) Boylan, Brian et al. "Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay" vol. 13, no. 1, 2015 Export RIS Citation Information.

:

Boylan, Brian ;

Rice, Anne S.

1 2015 | J Thromb Haemost. 13(1):47-53

:

BackgroundThe development of neutralizing antibodies, referred to as inhibitors, against factor VIII (FVIII) is a major complication associated with F...
Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations

CITE Title : Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations Personal Author(s) : Boylan, Brian;Rice, Anne S.;De Staercke, Christine;Eyster, M. Elaine;Yaish, Hassan M.;Knoll, Christine M.;Bean, Christopher J.;Miller, Connie H.; Corporate Authors(s) : Hemophilia Inhibitor Research Study Investigators Published Date : 6 2015;6-2015; Source : J Thromb Haemost. 13(6):1036-1042 URL : https://stacks.cdc.gov/view/cdc/32330 Boylan, Brian et al. (2015). Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. 13(6). Boylan, Brian et al. "Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations" 13, no. 6 (2015) Boylan, Brian et al. "Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations" vol. 13, no. 6, 2015 Export RIS Citation Information.

:

Boylan, Brian ;

Rice, Anne S.

6 2015 | J Thromb Haemost. 13(6):1036-1042

:

BackgroundHemophilia A (HA) is an X-linked bleeding disorder caused by a deficiency in factor VIII (FVIII). von Willebrand disease (VWD) is characteri...
The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: a New Online Resource

CITE Title : The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: a New Online Resource Personal Author(s) : Payne, Amanda B.;Miller, Connie H.;Kelly, Fiona M.;Soucie, J. Michael;Hooper, W. Craig; Published Date : 2 2013;2-2013; Source : Hum Mutat. 34(2):E2382-E2391 URL : https://stacks.cdc.gov/view/cdc/33838 Payne, Amanda B. et al. (2013). The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: a New Online Resource. 34(2). Payne, Amanda B. et al. "The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: a New Online Resource" 34, no. 2 (2013) Payne, Amanda B. et al. "The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: a New Online Resource" vol. 34, no. 2, 2013 Export RIS Citation Information.

:

Payne, Amanda B. ;

Miller, Connie H.

2 2013 | Hum Mutat. 34(2):E2382-E2391

:

Genotyping efforts in hemophilia A (HA) populations in many countries have identified large numbers of unique mutations in the Factor VIII gene (F8). ...
Food And Drug Administration Responses To The Challenges Of Aids

CITE Title : Food And Drug Administration Responses To The Challenges Of Aids Personal Author(s) : Meyer, H M Published Date : 07/01/1983 Source : Public Health Rep. 98(4):320-323 URL : https://stacks.cdc.gov/view/cdc/65988 Meyer, H M (1983). Food And Drug Administration Responses To The Challenges Of Aids. 98(4). Meyer, H M "Food And Drug Administration Responses To The Challenges Of Aids" 98, no. 4 (1983) Meyer, H M "Food And Drug Administration Responses To The Challenges Of Aids" vol. 98, no. 4, 1983 Export RIS Citation Information.

:

Meyer, H M

07/01/1983 | Public Health Rep. 98(4):320-323

:

Rarely has a public health issue emerged that has had impact on so many aspects of the responsibilities of the Food and Drug Administration. In a curi...
Achievements, challenges and unmet needs for haemophilia patients with inhibitors

CITE Title : Achievements, challenges and unmet needs for haemophilia patients with inhibitors Personal Author(s) : DARGAUD, Y.;PAVLOVA, A.;LACROIX-DESMAZES, S.;FISCHER, K.;SOUCIE, M.;CLAEYSSENS, S.;SCOTT, D.W.;d’OIRON, R.;LAVIGNE-LISSALDE, G.;KENET, G.;ETTINGSHAUSEN, C. ESCURIOLA;BOREL-DERLON, A.;LAMBERT, T.;PASTA, G.;NÉGRIER, C.; Published Date : 1 2016;1-2016; Source : Haemophilia. 22(Suppl 1):1-24 URL : https://stacks.cdc.gov/view/cdc/40935 DARGAUD, Y. et al. (2016). Achievements, challenges and unmet needs for haemophilia patients with inhibitors. 22 DARGAUD, Y. et al. "Achievements, challenges and unmet needs for haemophilia patients with inhibitors" 22 (2016) DARGAUD, Y. et al. "Achievements, challenges and unmet needs for haemophilia patients with inhibitors" vol. 22, 2016 Export RIS Citation Information.

:

DARGAUD, Y. ;

PAVLOVA, A.

1 2016 | Haemophilia. 22(Suppl 1):1-24

:

Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. Ho...
Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors

CITE Title : Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors Personal Author(s) : Miller, Connie H.;Boylan, Brian;Shapiro, Amy D.;Lentz, Steven R.;Wicklund, Brian M.; Published Date : 10 2017 Source : J Thromb Haemost. 15(10):1971-1976 URL : https://stacks.cdc.gov/view/cdc/50485 Miller, Connie H. et al. (2017). Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors. 15(10). Miller, Connie H. et al. "Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors" 15, no. 10 (2017) Miller, Connie H. et al. "Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors" vol. 15, no. 10, 2017 Export RIS Citation Information.

:

Miller, Connie H. ;

Boylan, Brian

10 2017 | J Thromb Haemost. 15(10):1971-1976

:

BackgroundThe Bethesda assay (BA) for measurement of factor VIII (FVIII) inhibitors called for quantitation of positive inhibitors using dilutions pro...

1 - 20 / 24